SANDIMMUN  NEORAL  25 MG CAPSULES Ísrael - enska - Ministry of Health

sandimmun neoral 25 mg capsules

novartis israel ltd - ciclosporin - capsules - ciclosporin 25 mg - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

SANDIMMUN  NEORAL  50 MG CAPSULES Ísrael - enska - Ministry of Health

sandimmun neoral 50 mg capsules

novartis israel ltd - ciclosporin - capsules - ciclosporin 50 mg - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

NEORAL cyclosporine capsule liquid filled Bandaríkin - enska - NLM (National Library of Medicine)

neoral cyclosporine capsule liquid filled

cardinal health - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 25 mg

Neoral Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

neoral

novartis new zealand ltd - ciclosporin 100 mg/ml;   - oral solution - 100 mg/ml - active: ciclosporin 100 mg/ml   excipient: corn oil dl-alpha tocopherol ethanol polyethylene glycol hydrogenated castor oil propylene glycol - transplantation indications solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

Neoral Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

neoral

novartis new zealand ltd - ciclosporin 100mg;   - soft gelatin capsule - 100 mg - active: ciclosporin 100mg   excipient: corn oil dl-alpha tocopherol ethanol gelatin glycerol iron oxide black polyethylene glycol hydrogenated castor oil propylene glycol   titanium dioxide - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

Neoral Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

neoral

novartis new zealand ltd - ciclosporin 10mg;   - soft gelatin capsule - 10 mg - active: ciclosporin 10mg   excipient: corn oil dl-alpha tocopherol ethanol gelatin glycerol polyethylene glycol hydrogenated castor oil propylene glycol   titanium dioxide - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).